218 related articles for article (PubMed ID: 32243655)
1. Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols.
Sitges M; Boluda B; Garrido A; Morgades M; Granada I; Barragan E; Arnan M; Serrano J; Tormo M; Miguel Bergua J; Colorado M; Salamero O; Esteve J; Benavente C; Pérez-Encinas M; Coll R; Martí-Tutusaus JM; Brunet S; Sierra J; Ángel Sanz M; Montesinos P; Ribera JM; Vives S;
Eur J Haematol; 2020 Aug; 105(2):138-147. PubMed ID: 32243655
[TBL] [Abstract][Full Text] [Related]
2. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.
Rogers HJ; Vardiman JW; Anastasi J; Raca G; Savage NM; Cherry AM; Arber D; Moore E; Morrissette JJ; Bagg A; Liu YC; Mathew S; Orazi A; Lin P; Wang SA; Bueso-Ramos CE; Foucar K; Hasserjian RP; Tiu RV; Karafa M; Hsi ED
Haematologica; 2014 May; 99(5):821-9. PubMed ID: 24463215
[TBL] [Abstract][Full Text] [Related]
3. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
[TBL] [Abstract][Full Text] [Related]
4. AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation.
Halaburda K; Labopin M; Houhou M; Niederwieser D; Finke J; Volin L; Maertens J; Cornelissen JJ; Milpied N; Stuhler G; Kröger N; Esteve J; Mohty M; Nagler A
Bone Marrow Transplant; 2018 Jun; 53(6):683-691. PubMed ID: 29670208
[TBL] [Abstract][Full Text] [Related]
5. Unusual findings of acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): A multicenter study.
Gong X; Yu T; Tang Q; Fu Y; Wu J; Zhu Y; Tu H; Ge H; Lu X; Gong D; Zhao X
Int J Lab Hematol; 2019 Jun; 41(3):380-386. PubMed ID: 30793839
[TBL] [Abstract][Full Text] [Related]
6. Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML.
Weisser M; Haferlach C; Haferlach T; Schnittger S
Leuk Lymphoma; 2007 Nov; 48(11):2145-51. PubMed ID: 17926191
[TBL] [Abstract][Full Text] [Related]
7. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases.
Haferlach C; Bacher U; Grossmann V; Schindela S; Zenger M; Kohlmann A; Kern W; Haferlach T; Schnittger S
Genes Chromosomes Cancer; 2012 Dec; 51(12):1079-85. PubMed ID: 22887804
[TBL] [Abstract][Full Text] [Related]
8. Impact of an Additional Chromosome on the Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Philadelphia Chromosome-Positive Acute Myeloid Leukemia in Adults.
Min GJ; Kim HJ; Yoon JH; Kwak DH; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1621-1628. PubMed ID: 29698793
[TBL] [Abstract][Full Text] [Related]
9. [Myelodysplastic syndromes and acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) abnormality].
Calderón-Cabrera C; Falantes JF; Bernal R; Pérez-Simón JA
Med Clin (Barc); 2015 Sep; 145(5):224-6. PubMed ID: 25190583
[No Abstract] [Full Text] [Related]
10. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia--analysis of 848 patients.
Visani G; Bernasconi P; Boni M; Castoldi GL; Ciolli S; Clavio M; Cox MC; Cuneo A; Del Poeta G; Dini D; Falzetti D; Fanin R; Gobbi M; Isidori A; Leoni F; Liso V; Malagola M; Martinelli G; Mecucci C; Piccaluga PP; Petti MC; Rondelli R; Russo D; Sessarego M; Specchia G; Testoni N; Torelli G; Mandelli F; Tura S
Leukemia; 2001 Jun; 15(6):903-9. PubMed ID: 11417475
[TBL] [Abstract][Full Text] [Related]
11. Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.
Brands-Nijenhuis AV; Labopin M; Schouten HC; Volin L; Socié G; Cornelissen JJ; Huynh A; Ljungman P; Malard F; Esteve J; Nagler A; Mohty M
Haematologica; 2016 Feb; 101(2):248-55. PubMed ID: 26589909
[TBL] [Abstract][Full Text] [Related]
12. De novo acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): a clinicopathologic and cytogenetic study of an entity recently added to the WHO classification.
Sun J; Konoplev SN; Wang X; Cui W; Chen SS; Medeiros LJ; Lin P
Mod Pathol; 2011 Mar; 24(3):384-9. PubMed ID: 21113141
[TBL] [Abstract][Full Text] [Related]
13. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461).
Byrd JC; Mrózek K; Dodge RK; Carroll AJ; Edwards CG; Arthur DC; Pettenati MJ; Patil SR; Rao KW; Watson MS; Koduru PR; Moore JO; Stone RM; Mayer RJ; Feldman EJ; Davey FR; Schiffer CA; Larson RA; Bloomfield CD;
Blood; 2002 Dec; 100(13):4325-36. PubMed ID: 12393746
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM.
Merz LE; Perissinotti AJ; Marini BL; Burke PW; Crouch A; Erba HP; Bixby D
Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):24-30. PubMed ID: 31711889
[TBL] [Abstract][Full Text] [Related]
15. Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation.
Chen Y; Cortes J; Estrov Z; Faderl S; Qiao W; Abruzzo L; Garcia-Manero G; Pierce S; Huang X; Kebriaei P; Kadia T; De Lima M; Kantarjian H; Ravandi F
J Clin Oncol; 2011 Jun; 29(18):2507-13. PubMed ID: 21555694
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories.
Cornelissen JJ; Breems D; van Putten WL; Gratwohl AA; Passweg JR; Pabst T; Maertens J; Beverloo HB; van Marwijk Kooy M; Wijermans PW; Biemond BJ; Vellenga E; Verdonck LF; Ossenkoppele GJ; Löwenberg B
J Clin Oncol; 2012 Jun; 30(17):2140-6. PubMed ID: 22564995
[TBL] [Abstract][Full Text] [Related]
17. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups.
Schoch C; Kern W; Schnittger S; Büchner T; Hiddemann W; Haferlach T
Haematologica; 2004 Sep; 89(9):1082-90. PubMed ID: 15377469
[TBL] [Abstract][Full Text] [Related]
18. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.
Delaunay J; Vey N; Leblanc T; Fenaux P; Rigal-Huguet F; Witz F; Lamy T; Auvrignon A; Blaise D; Pigneux A; Mugneret F; Bastard C; Dastugue N; Van den Akker J; Fière D; Reiffers J; Castaigne S; Leverger G; Harousseau JL; Dombret H; ; ; ; ;
Blood; 2003 Jul; 102(2):462-9. PubMed ID: 12649129
[TBL] [Abstract][Full Text] [Related]
19. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.
Grimwade D; Hills RK; Moorman AV; Walker H; Chatters S; Goldstone AH; Wheatley K; Harrison CJ; Burnett AK;
Blood; 2010 Jul; 116(3):354-65. PubMed ID: 20385793
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes.
Kuwatsuka Y; Miyamura K; Suzuki R; Kasai M; Maruta A; Ogawa H; Tanosaki R; Takahashi S; Koda K; Yago K; Atsuta Y; Yoshida T; Sakamaki H; Kodera Y
Blood; 2009 Feb; 113(9):2096-103. PubMed ID: 19126873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
